ArticleCancer2024

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Alain P Algazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.